Meixi Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Meixi Chen has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Luyao Zhou
Department of Medical Ultrasonics, Institute for Diagnostic and Interventional Ultrasound, the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, P.R. China
2 shared publications - Wenying Zhou
Department of Medical Ultrasonics, Affiliated Shenzhen Children's Hospital College of Medicine, Shantou University Shenzhen People's Republic of China
2 shared publications - Feng Chang
School of Pharmacy, University of Waterloo, Kitchener, ON N2G 1C5, Canada
1 shared publication - Martin Cooke
University of Waterloo
1 shared publication Meng Qiu
Department of Medical Ultrasonics, Institute for Diagnostic and Interventional Ultrasound, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, People’s Republic of China
1 shared publication- Mhd Wasem Alsabbagh
School of Pharmacy, Faculty of Science, University of Waterloo, Kitchener, Canada
1 shared publication
Latest Publications
- 23 May 2026
- Published by Wiley in Journal of Clinical Ultrasound
- Vol. 54 (8) , 2029-2032
Multimodal Ultrasound Findings of Pediatric Inflammatory Myofibroblastic Tumor in the Liver: A Case Report
An 8‐year‐old girl with persistent dizziness was discovered to have a lesion in the liver. Abdominal CT and MRI both favored the diagnosis of focal nodular hyperplasia (FNH). In contrast, multimodal ultrasound suggested a malignant nature of the lesion, for which biopsy was recommended. Following multidisciplinary consultation, the patient underwent laparoscopic resection of the lesion. Histopathology confirmed a borderline inflammatory myofibroblastic tumor of the liver. Postoperatively, the patient's clinical symptoms improved significantly, and she was discharged in stable condition.
- 23 May 2026
- Published by Wiley in Journal of Clinical Ultrasound
- Vol. 54 (8) , 2029-2032
Multimodal Ultrasound Findings of Pediatric Inflammatory Myofibroblastic Tumor in the Liver: A Case Report
An 8‐year‐old girl with persistent dizziness was discovered to have a lesion in the liver. Abdominal CT and MRI both favored the diagnosis of focal nodular hyperplasia (FNH). In contrast, multimodal ultrasound suggested a malignant nature of the lesion, for which biopsy was recommended. Following multidisciplinary consultation, the patient underwent laparoscopic resection of the lesion. Histopathology confirmed a borderline inflammatory myofibroblastic tumor of the liver. Postoperatively, the patient's clinical symptoms improved significantly, and she was discharged in stable condition.
- 9 June 2023
- Published by Springer Nature in Pediatric Radiology
- Vol. 53 (10) , 2004-2012
Utility of the pediatric liver contrast-enhanced ultrasound criteria in differentiating malignant and benign multifocal lesions
Background The pediatric liver contrast-enhanced ultrasound (CEUS) criteria were developed to improve the diagnostic performance of CEUS in differentiating pediatric benign and malignant liver lesions. However, the diagnostic performance of CEUS in the evaluation of multiple focal liver lesions in the pediatric population has not yet been fully evaluated. Objective To evaluate the diagnostic performance of the pediatric liver CEUS criteria in differentiating benign and malignant multifocal liver lesions in children. Materials and methods From April 2017 to September 2022, the CEUS characteristics of multifocal liver lesions in patients < 18 years were analyzed. Lesions classified as CEUS-1, CEUS-2 or CEUS-3 were considered benign and lesions classified as CEUS-4 or CEUS-5 were considered malignant. The diagnostic performance of the pediatric liver CEUS criteria (i.e. sensitivity, specificity, positive predictive value [PPV], negative predictive value [NPV] and accuracy) was assessed. Results After exclusion, 21 patients (median age, 36.0 months; range, 1.0–204 months; 7 boys) were included. There were significant differences in the serum alpha fetoprotein level (P= 0.039) and the presence of washout (P < 0.001) between children with malignant and benign lesions. The sensitivity, specificity, PPV, NPV and accuracy of the pediatric liver CEUS criteria were 100.0% (10/10), 90.9% (10/11), 90.9% (10/11), 100.0% (10/10) and 95.2% (20/21), respectively. Conclusion The pediatric liver CEUS criteria had excellent diagnostic performance in differentiating benign and malignant multifocal liver lesions in children.
- 9 June 2023
- Published by Springer Nature in Pediatric Radiology
- Vol. 53 (10) , 2004-2012
Utility of the pediatric liver contrast-enhanced ultrasound criteria in differentiating malignant and benign multifocal lesions
Background The pediatric liver contrast-enhanced ultrasound (CEUS) criteria were developed to improve the diagnostic performance of CEUS in differentiating pediatric benign and malignant liver lesions. However, the diagnostic performance of CEUS in the evaluation of multiple focal liver lesions in the pediatric population has not yet been fully evaluated. Objective To evaluate the diagnostic performance of the pediatric liver CEUS criteria in differentiating benign and malignant multifocal liver lesions in children. Materials and methods From April 2017 to September 2022, the CEUS characteristics of multifocal liver lesions in patients < 18 years were analyzed. Lesions classified as CEUS-1, CEUS-2 or CEUS-3 were considered benign and lesions classified as CEUS-4 or CEUS-5 were considered malignant. The diagnostic performance of the pediatric liver CEUS criteria (i.e. sensitivity, specificity, positive predictive value [PPV], negative predictive value [NPV] and accuracy) was assessed. Results After exclusion, 21 patients (median age, 36.0 months; range, 1.0–204 months; 7 boys) were included. There were significant differences in the serum alpha fetoprotein level (P= 0.039) and the presence of washout (P < 0.001) between children with malignant and benign lesions. The sensitivity, specificity, PPV, NPV and accuracy of the pediatric liver CEUS criteria were 100.0% (10/10), 90.9% (10/11), 90.9% (10/11), 100.0% (10/10) and 95.2% (20/21), respectively. Conclusion The pediatric liver CEUS criteria had excellent diagnostic performance in differentiating benign and malignant multifocal liver lesions in children.
National trends in population rates of opioid‐related mortality, hospitalization and emergency department visits in Canada between 2000 and 2017. A population‐based study
Background and aims: Existing assessments of the time‐trends of opioid‐related mortality, hospitalization and emergency department visits in Canada have relied mainly on provincial databases, while national assessments generally do not provide information before 2016. We aimed to estimate Canadian national time trends in opioid‐related mortality from 2000 to 2017 and opioid‐related hospitalization and emergency department visits between 2000 and 2012.Design: Retrospective cohort study.Setting and participants: Residents of all Canadian provinces and territories for which comparable data were available from 2000 to 2017.Measurements: We identified opioid‐related mortality, hospitalization and emergency department visits using validated algorithms using ICD codes from administrative databases. We calculated crude rates and sex‐ and age‐adjusted rates per million. For hospitalizations, we calculated case‐fatality, 90‐day and 365‐day all‐cause mortality and opioid‐related re‐hospitalization rates. We used Poisson regression to examine the significance of the time trend.Findings: From 2000 to 2017, the adjusted opioid mortality rate in Canada (outside Quebec) increased significantly by 592.9% (from 20.0 opioid deaths per million in 2000 to 118.3 in 2017). The highest year‐to‐year increases were from 2015 to 2016 (31.8%) and from 2016 to 2017 (52.2%). The adjusted hospitalizations doubled significantly during the study period (an increase of 103.7%, from 159.7 opioid hospitalizations per million Canadians in 2000 to 325.3 in 2012). The adjusted rate of emergency department visits increased significantly by 188.7% (from 280.6 per million in 2000 to 810.1 in 2012). Case‐fatality was 2.3% overall and was mainly constant during the study period. Both 90‐ and 365‐day all‐cause mortality increased significantly between 2000 and 2011 (from 1.7 to 3.1% and 3.9 to 7.4%, respectively), while re‐hospitalization for opioid‐related diagnoses was reduced (from 7.8 to 6.4% and 14.2 to 12.9%, respectively).Conclusions: Opioid‐related mortality, hospitalization and emergency department visits in Canada have been increasing gradually since 2000.
National trends in population rates of opioid‐related mortality, hospitalization and emergency department visits in Canada between 2000 and 2017. A population‐based study
Background and aims: Existing assessments of the time‐trends of opioid‐related mortality, hospitalization and emergency department visits in Canada have relied mainly on provincial databases, while national assessments generally do not provide information before 2016. We aimed to estimate Canadian national time trends in opioid‐related mortality from 2000 to 2017 and opioid‐related hospitalization and emergency department visits between 2000 and 2012.Design: Retrospective cohort study.Setting and participants: Residents of all Canadian provinces and territories for which comparable data were available from 2000 to 2017.Measurements: We identified opioid‐related mortality, hospitalization and emergency department visits using validated algorithms using ICD codes from administrative databases. We calculated crude rates and sex‐ and age‐adjusted rates per million. For hospitalizations, we calculated case‐fatality, 90‐day and 365‐day all‐cause mortality and opioid‐related re‐hospitalization rates. We used Poisson regression to examine the significance of the time trend.Findings: From 2000 to 2017, the adjusted opioid mortality rate in Canada (outside Quebec) increased significantly by 592.9% (from 20.0 opioid deaths per million in 2000 to 118.3 in 2017). The highest year‐to‐year increases were from 2015 to 2016 (31.8%) and from 2016 to 2017 (52.2%). The adjusted hospitalizations doubled significantly during the study period (an increase of 103.7%, from 159.7 opioid hospitalizations per million Canadians in 2000 to 325.3 in 2012). The adjusted rate of emergency department visits increased significantly by 188.7% (from 280.6 per million in 2000 to 810.1 in 2012). Case‐fatality was 2.3% overall and was mainly constant during the study period. Both 90‐ and 365‐day all‐cause mortality increased significantly between 2000 and 2011 (from 1.7 to 3.1% and 3.9 to 7.4%, respectively), while re‐hospitalization for opioid‐related diagnoses was reduced (from 7.8 to 6.4% and 14.2 to 12.9%, respectively).Conclusions: Opioid‐related mortality, hospitalization and emergency department visits in Canada have been increasing gradually since 2000.